Miconazole Nitrate; Polymyxin B Sulphate; Prednisolone Acetate

Verify with FDA CVM →

18 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
18
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Miconazole Nitrate; Polymyxin B Sulphate; Prednisolone Acetate

Administration Routes

Auricular (Otic)UnknownTopicalIntraocular

Species Affected

Dog 17
Cat 1

Most Affected Breeds

Shepherd Dog - Australian 2
Chihuahua 2
Shih Tzu 1
Poodle - Standard 1
Beagle 1
Bulldog - French 1
Pug 1
Boxer (German Boxer) 1
Pointing Dog - Hungarian Short-haired (Vizsla) 1
Retriever - Labrador 1

Most Reported Reactions

Lack of efficacy - NOS 3
Impaired hearing 3
Anaemia NOS 2
Not eating 2
Otorrhoea 2
Ear discharge 2
Other ear disorder NOS 2
Abnormal cytology 2
Loss of hearing 2
Other abnormal test result NOS 2
Deafness 2
Ear pruritus 2

Outcome Breakdown

Outcome Unknown
9 (50.0%)
Ongoing
7 (38.9%)
Recovered/Normal
2 (11.1%)

Data Summary

Metric Value
Total adverse event reports 18
Reports involving death 0
Case-fatality rate (reported events) 0.0%
Distinct species in reports 2
Distinct breeds in reports 16
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Miconazole Nitrate; Polymyxin B Sulphate; Prednisolone Acetate Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 18 adverse event reports referencing Miconazole Nitrate; Polymyxin B Sulphate; Prednisolone Acetate, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Miconazole Nitrate; Polymyxin B Sulphate; Prednisolone Acetate. Reported administration routes include Auricular (Otic), Unknown, Topical, Intraocular. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Miconazole Nitrate; Polymyxin B Sulphate; Prednisolone Acetate reports are Dog (17 reports), Cat (1 reports), with Dog accounting for the largest share. Within those species, Shepherd Dog - Australian (2), Chihuahua (2), Shih Tzu (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Miconazole Nitrate; Polymyxin B Sulphate; Prednisolone Acetate are Lack of efficacy - NOS (3), Impaired hearing (3), Anaemia NOS (2), Not eating (2). Of the 18 reports with a coded outcome, Outcome Unknown is the leading category at 50.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Miconazole Nitrate; Polymyxin B Sulphate; Prednisolone Acetate.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial